Shares of Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) are rallying Friday morning following back-to-back pre-market updates detailing positive clinical trial results and a major institutional financing package.
Quoin Pharmaceuticals shares are climbing with conviction. What’s behind QNRX gains?
Positive Phase 2/3 Interim Data for QRX003 Met Primary Endpoint
Early market enthusiasm centers on positive interim results from the company’s CL-QRX003-004 Phase 2/3 trial evaluating QRX003 4% lotion in patients with Netherton Syndrome.
An interim analysis of the first six patients to complete 12 weeks of treatment showed that 66.7% (4 of 6) achieved the target 1-grade or greater improvement in Investigator Global Assessment, meeting the pre-specified statistical significance threshold with a p-value of 0.0087.
